UNION therapeutics announces successful completion of the ADESOS Phase 2b study and presentation of data at the RAVE Conference 2024

Posted on by

ADESOS Phase 2b study evaluating orismilast as an oral treatment in 233 patients with moderate-to-severe atopic dermatitis (AD) has successfully completed Results from the ADESOS study have been selected for an oral presentation at the late breaking research sessions at the RAVE…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.